// App-Quantinova.ai

2312 : Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts

Researchers

Presenter

  • Ann Janssens

Principal Investigators

  • Francesco Rodeghiero

  • David Anderson

  • Beng Chong

  • Zoltan Boda

  • Ingrid Pabinger

  • Libor Cervinek

  • Xuena Wang

  • Angela Lopez

Medical Centers

  • University of Debrecen Medical and Health Science Center, Debrecen 4032, Hungary

  • University Hospital Masaryk University, Brno, Czech Republic

  • Division of Hematology and Hemostaseology, Medical University of Vienna, Wien, Austria

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • St George Hospital, Sydney, Australia

  • Universitaire Ziekenhuizen Leuven, Leuven, Belgium

  • Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy

Locations

  • Czech Republic

  • Canada

  • Italy

  • Austria

  • Australia

  • Belgium

  • Hungary

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Immune thrombocytopenia

  • Non-Hodgkin's Lymphoma

  • Renal insufficiency

  • Acute renal failure

  • Intracerebral hemorrhage

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Venous thrombosis

  • Lymphomas

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Romiplostim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved